LhARA Steering Group meeting #4

24^th September 2020 10:00 GMT

Notes

1. Notes of last meeting and actions arising:
   • KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     • Superceded.
   • KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     • Ongoing.
   • KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     • Ongoing.
   • KL: Ensure one representative per group at the next LhARA SG meeting.
     • Stands.
   • KL: Raise NIHR engagement with K.Gleeson.
     • Done.
   • KL: Seek PPI representative for SG.
     • Done. Welcome G. Jones and H. Hall.
   • KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
     • StG: Brm is not a radiotherapy research centre. Shoudl contact Manchester, Oxford, and Liverpool.
     • TG: Also need to contact with relevant medical physics groups.
   • KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     • Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
   • KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
     • Ongoing.
   • KL: Write to J.Clarke to ask for support to reach out to relevant industry.
     • Stands.
   • PA: Make contact with MTC to see how to make contact with relevant industry.
     • Stands
   • PA/KL will cooperate in drafting a letter.
     • Stands.
   • KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     • Stands.
   • KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     • Done. Meeting organised between A.Price and R.McLauchlan a success.

2. Update on progress: KL
   

3. Towards a PPI strategy for LhARA: GJ, HH
   
   • Main stem of strategy is to raise awareness with public and with patients. Then develop the engagement as the programme progresses.
   • Hard to see anything which would not benefit patients and also the health services. Patient input is vital all at all stages in the development of the programme.
   • Management of PPI will take time. Perhaps means that we need to include some resource. Marsden PPI outreach.
   • HH sits on various PPI advisory groups and can make links top various institutes.
     • Focus on engagement rather than involvement.
   • StG:
     • Agrees re effort involved in getting broad activity. Link to the Royal Marsden will be important.
   • KK:
     • BRC links important.
   • SG expressed it grateful recognition of the efforts of GJ and HH and the PPI representatives in drafting the two Lay Summaries so far. Both are/will be published.

4. Towards a clinician-engagement strategy for LhARA: StG
   
   • Neil Burnett and Adrian Crellin from Brm meeting might be pursuared to promote activity. Elizabeth Schuster, Rostoc is a researcher into the impact of microbeams.
   • There is a need to reach out to research-active clinicians. Probably should build up a target list in preparation for a webinar. A process such as that adopted by TP for the endstation/diagnostics development would be appropriate.
   • KK:
     • Noted the perception in the community that laser-ion beams are like nuclear fusion -- always 15 years away.
     • Critical to develop clear statement of what what the laser-hybrid technique can do that others cant.
   • Meeting:
     • We agreed to work towards a meeting of the relevant peer groups. TKW agreed to make contact with IoP at "top level".

5. ​Transformative Healthcare Technologies second call: KL/All
   Updated outline presented at the LhARA weekly meeting 22Sep20
   Discussion included:
   • PPI: GJ/HH
   • Clinician engagement: StG
   • Plan for preparation of proposal
     • Scope
     • Work packages
     • Stakeholders

6. DONMs
   
   • TBD

7. AoB
   

Agenda

1. Notes of last meeting and actions arising:
   • KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     • Superceded.
   • KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     • Ongoing.
   • KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     • Ongoing.
   • KL: Ensure one representative per group at the next LhARA SG meeting.
     • Stands.
   • KL: Raise NIHR engagement with K.Gleeson.
     • Done.
   • KL: Seek PPI representative for SG.
     • Done. Welcome G. Jones and H. Hall.
   • KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
   • KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     • Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
   • KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
     • Ongoing.
   • KL: Write to J.Clarke to ask for support to reach out to relevant industry.
     • Stands.
   • PA: Make contact with MTC to see how to make contact with relevant industry. PA/KL will cooperate in drafting a letter.
   • KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     • Stands.&&
   • KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     • Done. Meeting organised between A.Price and R.McLauchlan a success.

2. Update on progress: KL
   

3. Towards a PPI strategy for LhARA: GJ, HH
   

4. Towards a clinician-engagement strategy for LhARA: StG
   

5. ​Transformative Healthcare Technologies second call: KL/All
   Updated outline presented at the LhARA weekly meeting 22Sep20
   Discussion to include:
   • PPI
   • Clinician engagement:
   • Industrial engagement:
   • Plan for preparation of proposal
     • Scope
     • Work packages
     • Stakeholders
   • Next steps discussion

6. DONMs
   
   • TBD

7. AoB
   

---